A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Bae, Sang-Byung | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Kim, Ki Hwan | - |
dc.contributor.author | Nam, Seung-Hyun | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Lee, Jung-Hee | - |
dc.contributor.author | Park, Joon Seong | - |
dc.contributor.author | Jeong, Seong Hyun | - |
dc.contributor.author | Lee, Mark Hong | - |
dc.contributor.author | Kim, Yang-Soo | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Park, Keon Woo | - |
dc.contributor.author | Lee, Won-Sik | - |
dc.contributor.author | Lee, Sang Min | - |
dc.contributor.author | Lee, Jeong-Ok | - |
dc.contributor.author | Hyun, Myung Soo | - |
dc.contributor.author | Jo, Deog Yeon | - |
dc.contributor.author | Lim, Sung-Nam | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Cho, Do-Yeun | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Kim, Jeong-A | - |
dc.contributor.author | Park, Seong Kyu | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Kim, Soo-Jeong | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Yi, Hyeon Gyu | - |
dc.contributor.author | Moon, Joon Ho | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Joo, Young-Don | - |
dc.contributor.author | Kim, Hoon-Gu | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.contributor.author | Park, Moo-Rim | - |
dc.contributor.author | Song, Moo-Kon | - |
dc.contributor.author | Kim, Su-Youn | - |
dc.date.available | 2020-02-27T18:41:51Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-06-06 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6003 | - |
dc.description.abstract | Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM. Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS). Thirty-nine (22%) patients were aged >= 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. >= 2; p = 0.0002), beta(2)-microglobulin level (< 5.5 vs. = 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. = 35.1 mg/m(2); p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP. In conclusion, VMP is a feasible and effective front-line treatment for transplant-ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.subject | COMBINATION CHEMOTHERAPY | - |
dc.subject | PLUS MELPHALAN | - |
dc.subject | DEXAMETHASONE | - |
dc.subject | THERAPY | - |
dc.subject | PHASE-3 | - |
dc.subject | TRIAL | - |
dc.title | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000403236400058 | - |
dc.identifier.doi | 10.18632/oncotarget.16790 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.8, no.23, pp.37605 - 37618 | - |
dc.identifier.scopusid | 2-s2.0-85020194784 | - |
dc.citation.endPage | 37618 | - |
dc.citation.startPage | 37605 | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 8 | - |
dc.citation.number | 23 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | multiple myeloma | - |
dc.subject.keywordAuthor | aged | - |
dc.subject.keywordAuthor | bortezomib | - |
dc.subject.keywordAuthor | drug therapy | - |
dc.subject.keywordAuthor | combination | - |
dc.subject.keywordPlus | COMBINATION CHEMOTHERAPY | - |
dc.subject.keywordPlus | PLUS MELPHALAN | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PHASE-3 | - |
dc.subject.keywordPlus | TRIAL | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.